THE METABOLIC SYNDROME: RELATIONSHIP BETWEEN INSULIN SENSITIVITY AND THE ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPARs) IN SACCHARIDE AND LIPID METABOLISM

Rabha Ben Yahia, Radka Lichnovská, Tomáš Brychta

Institute of Physiology, Faculty of Medicine, Palacky University, 775 15 Olomouc, Czech Republic

Policlinic SPEA Olomouc, Czech Republic

e-mail: yahiarab@yahoo.com

Received: June 10, 2005; Accepted: September 25, 2005

Key words: PPARs/FABP/Insulin resistance/Dyslipidemia/Atherosclerosis/Agonists

INTRODUCTION

Obesity along with insulin resistance is the most frequent metabolic disease over the world. Incidence of obesity is equal to pandemic that represents a serious problem for the world health service of 21st century. This phenomenon threatens not only the Western populations, but also the newly industrialized countries; minorities in developed countries and populations of countries that replaced their traditional life style by the Western life style. About 2.1% of worldwide population have suffered from diabetes and an increase to 3% is expected by 2010. This is mostly type 2 diabetes mellitus associated with insulin resistance. Civilization-conditioned obesity is often associated with hyperinsulinemia and insulin resistance. These factors are considered to be the main syndromes of metabolic disease comprising also dyslipidemia of certain type (hypertriglyceridemia with decreased HDL-cholesterol) and hypertension. In 1980’s, Kaplan termed the complex of these diseases as “deadly quartet”. Now, this complex is called metabolic syndrome X or Raven’s syndrome. Progressed atherosclerosis is the main sequela of these diseases and mortality cause.

According to statistics, approximately every third adult suffers from this metabolic syndrome consisting of obesity associated with insulin resistance. Therefore efforts have been developed to find pathogenetic mechanisms of the origin of these diseases that represent predominant risk factors of cardiovascular morbidity and mortality. Individual components of metabolic syndrome are closely related and mutually conditioned, which highly increases the risk of cardiovascular diseases because the impact of these risk factors is not summed but multiplied. The PPARs are subgroups of nuclear hormone receptors of transcription factors mostly found in adipose tissue. They are described as important regulators of lipid and saccharide metabolism including insulin sensitivity; therefore they are taken as marker of metabolic syndrome. Their synthetic ligands could be used as drugs for insulin resistance and type 2 diabetes mellitus.

MARKERS INFLUENCING INSULIN SENSITIVITY

Up to now, numerous factors had been identified that are formed directly in adipose tissue and with increasing subcutaneous and intraabdominal fatty tissue they mostly negatively affect insulin metabolic efficiency. This is the case especially of fatty acids released in excess adipose tissue in obesity. Thus, fatty acid-binding proteins and their role in lipid metabolism seem to be crucial. Adipocytes also produce numerous polypeptides and cytokines, e.g. leptin, TNFα, adipin, resistin, which modulate tissue sensitivity to insulin effect and thus may be involved in etiopathogenesis of metabolic syndrome. Others factors which influence the lipid metabolism and are taken as marker of metabolic syndrome are PPARs. They represent homeostasis regulators of fatty acids and triacylglycerols in adipose tissue, which is indirectly but considerably associated with glucose metabolism homeostasis and insulin sensitivity. In this study we will focus on PPARs.

PPARs AS NUCLEAR HORMONE RECEPTORS

The PPARs are subgroups of nuclear hormone receptors of transcription factors. Ligand-activated transcription factors are various proteins that bind the activation molecule and then conform, thus being able entering the cell nucleus and modulate DNA transcription. PPARs regulate genes controlling lipid metabolism and in return lipid metabolites regulate their activity. They represent homeostasis regulators of fatty acids and triacylglycerols in adipose tissue, which is indirectly but considerably associated with glucose metabolism homeostasis and insulin sensitivity (see Fig. 1.).
The PPARs are considered to be lipid-activated nuclear receptors and are known to either induce transcription via PPAR response elements or inhibit transcription by inhibiting NFκb and AP-1 signalling. The binding of lipid ligands and their synthetic counterparts lead up to the recruitment of transcriptional coactivator proteins that influence the rate of RNA polymerase II transcription. The PPARs are expressed in endothelial cells which are constantly exposed to shear forces from the flow of blood along their surface. Jorge Plutzky from Harvard medical school confirmed with his recent studies the role of PPARs in vascular biology and atherosclerosis and affirmed its expression and its regulation of important target genes in relevant cell types. He provided a rationale for the large-scale cardiovascular trials with PPAR agonists now underway and their part in diabetes, inflammation and atherosclerosis.

In concert, all these findings and conformations reveal previously unrecognized PPAR-sensitive pathways involved in maintenance of cholesterol homeostasis, lipid metabolism and inhibition of inflammatory responses in macrophage may be used for a development of new therapies of atherosclerosis and diabetes type II.

**SUBGROUPS OF PPARS**

Three types of PPAR are defined: PPARα, PPARβ (also termed as beta, NUC-1 or FAAR) and PPARγ. These PPAR Subgroups have different functions and diverse expression in various tissues.

PPARα are in humans expressed by liver, striated muscles, kidney and cell endothelium. It participates in regulation of lipoprotein metabolism fatty acid oxidation, fatty acid uptake by cells and their alteration represents one of factors of originated disorder of lipid metabolism.

PPARα agonists decrease TAG plasma concentrations by decreasing apolipoprotein C-III concentrations and increasing the expression of lipoprotein lipase. It has been demonstrated that apo AV is a PPARα target gene and supporting its role as a major mediator for how fibrates reduce triacylglycerols in human’s and mice’s plasma. Many preclinical analyses provided that activation of PPARα represents very important pathway which influences vascular function directly and indirectly by altering gene expression. PPARα activation induces beneficial effects on lipid metabolism, on glucose homeostasis, on endothelial function and on vessel wall inflammation. PPARα agonists can modify the process of atherosclerosis especially in patients with metabolic syndrome or type 2 diabetes. Sweetly to all of this fact PPARα agonists like the statins are beginning to have numerous additional anti-inflammatory and anti-atherosclerotic actions so they take an important place in the therapeutic arsenal for cardiovascular disease prevention.

PPARβ/δ was found in various tissues. In animals they are involved in differentiation of oloogendroytes and spermatogenesis. PPARβ were also found in human tissues but their distribution and function have been studied in detail yet.

Its role was investigated in skeletal muscle, by performing Affymetrix microarray gene expression analysis in rat treated with the PPARβ/δ agonist GW501516. Activation PPARβ/δ by this agonist evoked the clustered expression of molecules governing fatty acid oxidation and energy expenditure. Most important effect of GW501516 on tow distinct models of metabolic syndrome is embellished fatty acid oxidation in skeletal muscle, protected against dietinduced obesity and improved glucose tolerance and insulin sensitivity. So we can affirm that PPARβ/δ agonist could be used as ideal pharmacological target for intervention and prevention of obesity and associated metabolic diseases like type 2 diabetes mellitus. However PPARβ/δ as a nuclear receptor which regulates atherosclerosis-relevant genes by binding to upstream promoter elements is ubiquitously expressed and by its activation causes a decrease of plasma triacylglycerol and an elevation of HDL-C. The increase of HDL production stimulates reverse cholesterol transport. Consequently, specific PPARβ/δ agonists could be used as anti-dyslipidemic and anti-atherosclerotic drugs. Moreover the PPARβ/δ agonists have a therapeutic effect also for obesity.

PPARγ are mostly expressed in adipose tissue. mRNA for PPARγ and corresponding protein were found in human skeletal muscles, liver, kidney, intestine, urinary bladder and spleen. The corresponding protein for PPARγ was detected also in the myocardium. mRNA for PPARγ exist in three isoforms (γ1, γ2, γ3) but PPARγ corresponding protein only in two different isoforms (γ1, γ3).

PPARγ play a key role in adipogenesis and are major regulators of the reaction of thrifty gene responsible for effective energy storage. By influencing adipocyte regulation and stimulating neutral fat formation and storage, they represent an important factor in lipid and glucose metabolism regulation. Their synthetic ligands are efficient medicaments of insulin resistance and type 2 diabetes. Recent studies have proved that these nuclear receptors are significantly involved in transcription control and many other cell processes, e.g. control of cell cycle, carcinogenesis, inflammation, atherosclerosis and...
immunomodulation. PPARγ activators (e.g. thiazolidinediones) increase plasma adiponectin concentration in insulin-resistant individuals and type 2 diabetic patients via increased expression and secretion in adipocytes. PPARγ is expressed in two major isoforms \( \gamma_1, \gamma_2 \). Both the structurally different isoforms are products of one gene. No functional differences were reported (see Fig. 2.). There are several factors that may affect insulin metabolism just by adiponectin secretion modulation by adipocytes. One of these factors is TNFα, which decreases adiponectin expression and secretion. PPARγ activation reduces negative metabolic effects of TNFα on adipocytes\(^4\)\(^,\)\(^7\),\(^10\),\(^12\),\(^13\),\(^23\),\(^22\),\(^28\),\(^31\),\(^32\).

**THIAZOLIDINEDIONES (TZDS) AND INSULIN SENSITIVITY**

TZD represent a new category of peroral diabetics improving insulin resistance. The mechanism of their effect consists of activation of nuclear receptors PPARγ, so that TZD influence the expression of genes coding proteins necessary for insulin effect. TZDs increase pancreas beta-cell activity and correct the glucose uptake in peripheral tissues. They also positively influence the blood pressure and rectify the lipid spectrum. In adipose tissue they favourably change the profile of secretion of hormones associated with insulin resistance (decrease of TNFα, resistin, leptin and increased adiponectin level) and improve the production of free fatty acids. Through improved sensitivities to insulin, TZD affect comprehensively all components of metabolic syndrome. Clinically, TZD have been used as drugs of second choice in combination with metformin or sulphonylurea derivatives – they cannot be used in monotherapy (except e.g. USA, Finland, Switzerland, Sweden) or in combination with insulin. A standard antidiabetic therapy effects the elimination of subsequent complications associated with type 2 DM progression, however their effects are minimally. Recent studies report that the use of TZDs either in monotherapy or in combination with used antiabetics shows much more effect on metabolic processes that eliminate progression of type 2 DM complications. Therefore it is recommended to apply TZD at the beginning of the therapy of type 2 DM\(^2\),\(^3\),\(^16\),\(^17\),\(^18\),\(^21\).

Synthetic PPARγ agonists (e.g. TZDs) confer insulin sensitizing and anti-diabetic effects in animals and humans; they are also implicated as having anti-inflammatory and anti-atherosclerotic effects. The development of agents with dual PPARγ and PPARα activity provides for a new approach to achieve additional efficacy with respect to controlling dyslipidemia in association with glucose lowering activity. An alternative approach is the recent discovery of synthetic PPARγ ligands with partial agonist or antagonist activity (selective PPARγ modulators) (see Fig. 2.).

**THIAZOLIDINEDIONES (TZDS) AND PLASMA LIPID SPECTRUM**

People with type 2 diabetes frequently have a dyslipidemia characterized by elevated triacylglycerols, reduced high-density cholesterol and preponderance of small dense LDL particles. Importantly several studies have reported that the different components of dyslipidemia are related to insulin resistance measured either by using as a parameter either the HOMA index or insulin stimulated glucose utilization rate during insulin clamp studies. Since TZDs improve insulin sensitivity it may be expected that the effect of TZDs on lipid parameters could also be positive. Currently two agents rosiglitazone and pioglitazone are available for treatment of type 2 diabetic patients. Growing data evidence that these drugs also cause significant changes in plasma lipid concentrations. TZDs activate PPAR and modulate the expression of several genes regulating glucose and lipid metabolism. TZDs promote triacylglycerol storage in adipocyte and this is associated with reduction of FFA release into circulation. FFA flux into the liver is one major factor driving VLDL assembly and secretion from the liver. Since both pioglitazone and rosiglitazone lower plasma FFA levels to a similar magnitude one would expect a similar reduction of plasma triacylglycerol (TAG) levels. However the response of plasma TAG to TZDs has been variable in type 2 diabetic subjects. Pioglitazone seems to reduce plasma TAG level whereas rosiglitazone has minimal or no effect on plasma TAG. This difference of plasma TAG response raises the question; do TZDs have some direct effect on VLDL assembly/secrection in the liver? This option is supported by the findings that in man TZDs seems to reduce liver fat that is closely connected with the elevation of plasma TAG level. Available data evidence that TZD compounds consistently increases plasma HDL cholesterol despite the differences in plasma TAG response.
The change of HDL cholesterol has been between ca. 5–15 % in different clinical trials. The effects of TZDs on apo A-I level seem to be variable and either increase or no change has been reported. Recent findings from in vitro experiments suggest that PPAR (like PPAR activators stimulate the ABCA 1 pathway and cholesterol efflux from the cells. This mechanism provides a good explanation for the increase of HDL cholesterol without major changes of apo A-I in clinical trials. The change of LDL cholesterol has also been variable in clinical trials. The use of rosiglitazone has been associated with a small but consistent increase of LDL cholesterol whereas the response to pioglitazone seems to be neutral. Available data on the response of apo B 100 to TZDs have been inconsistent. Why TZDs exert different effects on LDL is an open issue. Preliminary data suggest that both pioglitazone and rosiglitazone may decrease the amount of small dense LDL particles but the mechanism of this action is not yet resolved. In conclusion TZDs seem to have potentially beneficial actions on lipid parameters independently on their effects on blood glucose control. However the specific sites of PPAR (activators in lipid metabolism in man are still not well understood13, 5, 28.

CONCLUSION

Metabolic syndrome is the most frequent disease and considered as the predominant risk factor of cardiovascular diseases. Numerous factors had been identified that are formed directly in adipose tissue and with increasing subcutaneous and intraabdominal fatty tissue they mostly negatively affect insulin metabolic efficiency. Transcription factor PPARγ is an important parameter regulating genes that control lipid and saccharide metabolism. The role of PPARγ in regulation of saccharide and lipid homeostasis can be modulated by various factors e.g. fatty acid-binding proteins, adiponectin ect. Adipocytes of obese individuals produce excessively some cytokines (including leptin and TNFα) that reduce sensitivity of many tissues to insulin effect. Recent papers indicate the existence of mutual relations among these cytokines, nuclear receptors PPARγ and adiponectin. PPAR agonists e.g. TZDs and fibrates have benefit effect in the treatment of insulin resistance associated with metabolic syndrome and in prevention of its cardiovascular complication.

REFERENCES

The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism